Skip to main content

Table 1 Association between TNFAIP8 expression and clinicopathological characteristics of NSCLC patients

From: TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway

Variable

All patients

TNFAIP8 expression

P

High (%)

Low (%)

(n = 196)

(n = 106)

(n = 90)

Smoking

 Never

93

53 (50)

40 (44)

0.438

 Ever

103

53 (50)

50 (56)

Gender

 Male

129

68 (64)

61 (68)

0.594

 Female

67

38 (36)

29 (32)

Age (years)

  < 60

129

71 (67)

58 (64)

0.709

  ≥ 60

67

35 (33)

32 (36)

Differentiation

 Well

18

12 (11)

6 (7)

0.263

 Moderate

87

42 (40)

45 (50)

 Poor

91

52 (49)

39 (43)

Histological cell type

 Adenocarcinoma

122

70 (66)

52 (58)

0.235

 Squamous cell carcinoma

74

36 (34)

38 (42)

pStage

 I

93

43 (40.5)

50 (56)

0.022*

 II

40

20 (19)

20 (22)

 III

63

43 (40.5)

20 (22)

pT classification

 T1

51

20 (19)

31 (34)

0.034*

 T2

129

75 (71)

54 (60)

 T3/4

16

11 (10)

5 (6)

Lymph node metastasis

0.005*

 Present

82

54 (51)

28 (31)

 

 Absent

114

52 (49)

62 (69)

 

Adjuvant therapy

 Yes

121

62 (58)

59 (66)

0.311

 No

75

44 (42)

31 (34)

  1. Abbreviations: NSCLC non-small cell lung cancer, pTNM stage tumor, node, metastasis (pathological stage), pT pathological T stage, n number of patients. Ever: smoking at any time from the beginning of life. P value: the difference of clinicopathological characteristics between the TNFAIP8 high expression group and low expression group. *P < 0.05 was considered statistically significant